Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2015 | 71 | 10 |
Tytuł artykułu

Wpływ pokarmu oraz sposobu dawkowania na farmakokinetykę cymikoksybu u psów

Treść / Zawartość
Warianty tytułu
Effect of food and dosage on cimicoxib pharmacokinetics in dogs
Języki publikacji
Cimicoxib (CX) is a new non-steroidal anti-inflammatory drug from the “coxib” family, designed for dogs. In the available literature there is little information on the pharmacokinetics of CX. The aim of this study was to evaluate the effect of food intake on the pharmacokinetic characteristics of cimicoxib. Additionally, the pharmacokinetic profile after the administration of precise doses of CX (2 mg/kg b.w.) and an approximate dose (i.e. 80 mg tablet for animals of about 40 kg) were estimated. CX concentrations were determined by a HPLC validated method. The results of pharmacokinetic analysis were similar in both studies, regardless of the dose and the degree of filling of the gastrointestinal tract (fasted, fed). In addition, we estimated the duration of the minimum effective concentration (MEC), which turned out to be similar for all the concentrations tested. The results show that neither small variations in dosage nor the presence of food in the gastrointestinal tract change the therapeutic efficacy of the analgesic in terms of its blood concentration.
Opis fizyczny
  • Zakład Farmakologii, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul. Akademicka 13, 20-950 Lublin
  • Zakład Farmakologii, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul. Akademicka 13, 20-950 Lublin
  • Institute of Veterinary Science, College of Veterinary Medicine, Chungnam National University, Daejeon 305-764, South Korea
  • School of Veterinary Science, University of Queensland, Gatton Campus, Gatton, Queensland, 4343, Australia
  • Institute of Veterinary Science, College of Veterinary Medicine, Chungnam National University, Daejeon 305-764, South Korea
  • Department of Veterinary Clinics, Veterinary Teaching Hospital, University of Pisa, Via Livornese (lato monte) 1, San Piero a Grado, 56122 Pisa, Italy
  • 1. Almansa C., Alfon J., de Arriba A. F., Cavalcanti F. L., Escamilla I., Gomez L. A., Miralles A., Soliva R., Bartroli J., Carceller E., Merlos M., Garcia-Rafanell J.: Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. J. Med. Chem. 2003, 46, 3463-3475.
  • 2. Autefage A., Palissier F. M., Asimus E., Pepin-Richard C.: Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet. Rec. 2011, 168, 617.
  • 3. Bienhoff S. E., Smith E. S., Roycroft L. M., Roberts E. S.: Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet. Surg. 2012, 41, 336-344.
  • 4. Dongowski G., Fritzsch B., Giessler J., Hartl A., Kuhlmann O., Neubert R. H.: The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. Eur. J. Pharm. Biopharm. 2005, 60, 147-151.
  • 5. EMA/CVMP Report. European Medicines Agency. Veterinary medicines and product data management, 2011 (EMA/CVMP/513842/2011).
  • 6. Emmerich I. U.: New drugs for small animals in 2011. Tierarztl. Prax. Ausg. K. Kleintiere. Heimtiere. 2012, 40, 351-362.
  • 7. Giorgi M.: Veterinary pharmacology: Is it still pharmacology’s cinderella? Clin. Exp. Pharmacol. P. 2012, 2, 103.
  • 8. Giorgi M., Kim T. W., Saba A., Rouini M. R., Yun H., Ryschanova R., Owen H.: Detection and quantification of cimicoxib, a novel COX-2 inhibitor, in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology. J. Pharm. Biomed. Anal. 2013, 83, 28-33.
  • 9. Giorgi M., Saccomanni G., Del Carlo S., Manera C., Lavy E.: Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. Vet. J. 2012, 193, 246-250.
  • 10. Grandemange E., Fournel S., Woehrle F.: Efficacy and safety of cimicoxib in the control of perioperative pain in dogs. J. Small. Anim. Pract. 2013, 54, 304-312.
  • 11. Hanson P. D., Brooks K. C., Case J., Conzemius M., Gordon W., Schuessler J., Shelley B., Sifferman R., Drag M., Alva R., Bell L., Romano D., Fleishman C.: Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. Vet. Ther. 2006, 7, 127-140.
  • 12. Hoffman J., Perkins C.: Veterinary Generics: An Enigma among Niche Markets. J. Generic. Med. 2008, 5, 281-289.
  • 13. Moreau M., Daminet S., Martel-Pelletier J., Fernandes J., Pelletier J. P.: Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J. Vet. Pharmacol. Ther. 2005, 28, 81-86.
  • 14. Paulson S. K., Vaughn M. B., Jessen S. M., Lawal Y., Gresk C. J., Yan B., Maziasz T. J., Cook C. S., Karim A.: Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J. Pharmacol. Exp. Ther. 2001, 297, 638-645.
  • 15. Reymond N., Speranza C., Gruet P., Seewald W., King J. N.: Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. Vet. Pharmacol. Ther. 2012, 35, 175-183.
  • 16. Rigau D., De la Cruz G., Pena J., Carbo M., Ramis I., Izquierdo I.: UR-8880, a new potent COX2 inhibitor: First administration into man to assess its tolerability, pharmacokinetics and pharmacodynamics. Ann. Rheum. Dis. 2003, 62, 413-413.
  • 17. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P.: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 1994, 91, 12013-12017.
  • 18. Sorbera L. A., Ramis I.: Cimicoxib. Antiarthritic, analgesic, COX-2 inhibitor. Drug. Fut. 2004, 29, 325-330.
  • 19. Toutain P. L., Lees P.: Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. J. Vet. Pharmacol. Ther. 2004, 27, 467-477.
  • 20. Vardeh D., Wang D., Costigan M., Lazarus M., Saper C. B., Woolf C. J., Fitzgerald G. A., Samad T. A.: COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. J. Clin. Invest. 2009, 119, 287-294.
  • 21. Welling P. G.: Influence of food and diet on gastrointestinal drug absorption: a review. J. Pharmacokinet. Biop. 1977, 5, 291-334.
  • 22. Zhang Y., Shaffer A., Portanova J., Seibert K., Isakson P. C.: Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther. 1997, 283, 1069-1075.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.